Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Cash from Financing Activities for 8 consecutive years, with $18.8 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 7174.81% year-over-year to $18.8 million; the TTM value through Mar 2026 reached $1.0 billion, up 295.23%, while the annual FY2025 figure was $990.7 million, 62.72% up from the prior year.
  • Cash from Financing Activities hit $18.8 million in Q1 2026 for Kymera Therapeutics, down from $705.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $705.2 million in Q4 2025 and bottomed at -$206000.0 in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $104.4 million, with a median of $2.0 million recorded in 2022.
  • Year-over-year, Cash from Financing Activities crashed 100.14% in 2023 and then soared 121904.85% in 2024.
  • Kymera Therapeutics' Cash from Financing Activities stood at $2.0 million in 2022, then decreased by 0.97% to $1.9 million in 2023, then surged by 42.97% to $2.8 million in 2024, then surged by 25405.21% to $705.2 million in 2025, then crashed by 97.34% to $18.8 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $18.8 million, $705.2 million, and $39.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.